Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 68 Paragraph 2: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 5: | Line 5: | ||
Paragraph 2 | Paragraph 2 | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00137-Mon-che ++ TAG-00245-Spo-ten ++ TAG-00231-Per-ung ++ TAG-00329-Saf-lne ++ TAG-00220-Inv-agn | ||
| | |RefModule=4 | ||
| | |RefUnit=4.3.1 | ||
}} | }} | ||
| Line 15: | Line 15: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 4 — Unit 4.3.1 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 32: | Line 35: | ||
| | | | ||
|- | |- | ||
! Tags | ! Tags | ||
| | | [[Glossary:TAG-00137-Mon-che|Monitoring]], [[Glossary:TAG-00245-Spo-ten|Sponsor responsibilities]], [[Glossary:TAG-00231-Per-ung|Performance study]], [[Glossary:TAG-00329-Saf-lne|Safety]], [[Glossary:TAG-00220-Inv-agn|IVD]] | ||
|- | |||
| | |||
|- | |||
| | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 |
| Validity area | EU |
| Scope(s) | IVD |
| Document name | Regulation (EU) 2017/746 - in vitro diagnostic medical devices |
| Version / Revision | 20-Mar-2023 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 4 — Unit 4.3.1 |
| Scope | IVD |
| Document part | Article 68
Paragraph 2 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Monitoring, Sponsor responsibilities, Performance study, Safety, IVD |
| Comment | Monitoring obligations in performance study (IVDR) |
Content
Conduct of a performance study
2. In order to verify that the rights, safety and well-being of subjects are protected, that the reported data are reliable and robust, and that the conduct of the performance study is in compliance with the requirements of this Regulation, the sponsor shall ensure adequate monitoring of the conduct of a performance study. The extent and nature of the monitoring shall be determined by the sponsor on the basis of an assessment that takes into consideration all characteristics of the performance study including the following:
(a) the objective and methodology of the performance study; and
(b) the degree of deviation of the intervention from normal clinical practice.
